1 EXHIBIT 10.2 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. LEXVISION(TM) DATABASE AND COLLABORATION AGREEMENTAnd Collaboration Agreement • August 14th, 2001 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Delaware
FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENTAnd Collaboration Agreement • January 2nd, 2024 • CG Oncology, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT (“First Amendment”) is effective as of September 15, 2022 (the “First Amendment Effective Date”) by and between Kissei Pharmaceutical Co., Ltd., a corporation duly organized and existing under the lases of Japan and having its registered office at 19-48, Yoshino, Matsumoto, Nagano Prefecture, Japan (“Kissei”), and CG Oncology, Inc. (formerly known as Cold Genesys, Inc.), a company organized and existing under the laws of the state of Delaware, United States, located at 400 Spectrum Center Drive, Suite #2040 Irvine, CA 92618 (“CG”). Kissei and CG are each referred to herein by name or, individually, as a “Party” and together as the “Parties.”
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. COMPANION DIAGNOSTICS...And Collaboration Agreement • February 19th, 2021 • Prometheus Biosciences, Inc. • Pharmaceutical preparations • New York
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRVIATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” AMENDMENT NO. 3 TO GLOBAL...And Collaboration Agreement • February 28th, 2022 • BioAtla, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 3 TO GLOBAL CO-DEVELOPMENT AND COLLABORATION AGREEMENT (this “Amendment”), dated as of November 18, 2021 (the “Amendment Effective Date”), is among BioAtla, Inc., a Delaware corporation (“BioAtla”), BeiGene, Ltd., a Cayman Islands corporation (“BeiGene Cayman”), and BeiGene Switzerland GmbH, a company organized under the laws of Switzerland having an address of c/o VISCHER AG, Aeschenvorstadt 4, 4051 Basel, Switzerland (“BeiGene Switzerland”) (BeiGene Cayman and BeiGene Switzerland together, “BeiGene”). BioAtla and BeiGene are each referred to as a “Party” and collectively as the “Parties”.
SECOND AMENDMENT TO THE TECHNOLOGY LICENSE, DEVELOPMENT, RESEARCH AND COLLABORATION AGREEMENTAnd Collaboration Agreement • November 9th, 2012 • Amyris, Inc. • Industrial organic chemicals
This Second Amendment (the “Second Amendment”) to the Technology License, Development, Research and Collaboration Agreement entered into as of June 21, 2010 (as amended by that certain First Amendment dated as of November 23, 2011 (the “First Amendment”), the “Agreement”) is entered into as of July 30, 2012 (the “Second Amendment Date”) by and between:
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE, SUPPLY, MARKETING, DISTRIBUTION AND...And Collaboration Agreement • May 9th, 2018 • Osmotica Pharmaceuticals LTD • Pharmaceutical preparations
This License, Supply, Marketing, Distribution and Collaboration Agreement (hereinafter called the “Agreement”) is made and entered into as of November 24, 2003 (hereinafter “Date of Agreement”) by and between Orion Corporation, a company duly organized and existing under the laws of Finland and having its principal offices at Orionintie 1, (P.O. Box 65), 02200 Espoo, Finland (hereinafter “Orion”), and Upsher-Smith Laboratories, Inc., a company duly organized and existing under the laws of Minnesota and having its principal office at 6701 Evenstad Drive, Maple Grove, Minnesota, USA (hereinafter “USL”). Orion and USL may also be described individually as “Party” or collectively as “Parties”.
RESEARCH, LICENSE, AND COLLABORATION AGREEMENT between DYADIC INTERNATIONAL INC. and JANSSEN BIOTECH, INC. Dated as of [●]And Collaboration Agreement • December 17th, 2021 • Dyadic International Inc • Biological products, (no disgnostic substances)
This Research, License, and Collaboration Agreement (the “Agreement”) is made and entered into as of [●] (the “Effective Date”) by and between Dyadic International Inc., (“Dyadic”), and Janssen Biotech, Inc., a Pennsylvania corporation (“Janssen”). Dyadic and Janssen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
License and Collaboration Agreement dated as of September 15, 2021 by and among Orphan Technologies Limited, Tortola (British Virgin Islands),Branch Office in Switzerland,Rapperswil Jona,c/o Neovii Pharmaceuticals AG,Zuercherstrasse 19, CH-8640...And Collaboration Agreement • October 29th, 2021 • Travere Therapeutics, Inc. • Pharmaceutical preparations • New York
Number of Annex Name of Annex Annex 1 Definitions Annex 2.1(a) Licensed Patents Annex 2.2(a) Affiliates and Third Parties Annex 2.4 Upstream License Agreements Annex 3.1(b) Clinical Development Plan Annex 3.2(b) Technical Development Plan Annex 4(g) DUPRO (DUPLEX/PROTECT) Limited Access Data Protocol Annex 8.4(a) Product Trademarks Annex 8.4(g) Existing Domain Names
